These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 8393116)

  • 1. (3SR,4aRS,6RS,8aRS)-6-[2-(1H-tetrazol-5-yl)ethyl]decahydroisoquinoline-3 - carboxylic acid: a structurally novel, systemically active, competitive AMPA receptor antagonist.
    Ornstein PL; Arnold MB; Augenstein NK; Lodge D; Leander JD; Schoepp DD
    J Med Chem; 1993 Jul; 36(14):2046-8. PubMed ID: 8393116
    [No Abstract]   [Full Text] [Related]  

  • 2. (3SR,4aRS,6SR,8aRS)-6-(1H-tetrazol-5-yl)decahydroisoquinoline-3-carboxylic acid, a novel, competitive, systemically active NMDA and AMPA receptor antagonist.
    Ornstein PL; Arnold MB; Allen NK; Leander JD; Tizzano JP; Lodge D; Schoepp DD
    J Med Chem; 1995 Dec; 38(25):4885-90. PubMed ID: 8523401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-activity studies of 6-substituted decahydroisoquinoline-3-carboxylic acid AMPA receptor antagonists. 2. Effects of distal acid bioisosteric substitution, absolute stereochemical preferences, and in vivo activity.
    Ornstein PL; Arnold MB; Allen NK; Bleisch T; Borromeo PS; Lugar CW; Leander JD; Lodge D; Schoepp DD
    J Med Chem; 1996 May; 39(11):2232-44. PubMed ID: 8667366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-activity studies of 6-(tetrazolylalkyl)-substituted decahydroisoquinoline-3-carboxylic acid AMPA receptor antagonists. 1. Effects of stereochemistry, chain length, and chain substitution.
    Ornstein PL; Arnold MB; Allen NK; Bleisch T; Borromeo PS; Lugar CW; Leander JD; Lodge D; Schoepp DD
    J Med Chem; 1996 May; 39(11):2219-31. PubMed ID: 8667365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo antagonism of AMPA receptor activation by (3S, 4aR, 6R, 8aR)-6-[2-(1(2)H-tetrazole-5-yl) ethyl] decahydroisoquinoline-3-carboxylic acid.
    Schoepp DD; Lodge D; Bleakman D; Leander JD; Tizzano JP; Wright RA; Palmer AJ; Salhoff CR; Ornstein PL
    Neuropharmacology; 1995 Sep; 34(9):1159-68. PubMed ID: 8532186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The neuroprotective effects of the decahydroisoquinoline, LY 215490; a novel AMPA antagonist in focal ischaemia.
    Gill R; Lodge D
    Neuropharmacology; 1994 Dec; 33(12):1529-36. PubMed ID: 7760975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Supraspinal and spinal alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid and N-methyl-D-aspartate glutamatergic control of the micturition reflex in the urethane-anesthetized rat.
    Yoshiyama M; de Groat WC
    Neuroscience; 2005; 132(4):1017-26. PubMed ID: 15857706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective protection against AMPA- and kainate-evoked neurotoxicity by (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahyd roisoquinoline- 3-carboxylic acid (LY293558) and its racemate (LY215490).
    Schoepp DD; Salhoff CR; Fuson KS; Sacaan AI; Tizzano JP; Ornstein PL; May PC
    J Neural Transm (Vienna); 1996; 103(8-9):905-16. PubMed ID: 9013384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacology of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)/kainate antagonists and their role in cerebral ischaemia.
    Gill R
    Cerebrovasc Brain Metab Rev; 1994; 6(3):225-56. PubMed ID: 7529037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A hippocampal GluR5 kainate receptor regulating inhibitory synaptic transmission.
    Clarke VR; Ballyk BA; Hoo KH; Mandelzys A; Pellizzari A; Bath CP; Thomas J; Sharpe EF; Davies CH; Ornstein PL; Schoepp DD; Kamboj RK; Collingridge GL; Lodge D; Bleakman D
    Nature; 1997 Oct; 389(6651):599-603. PubMed ID: 9335499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of decahydroisoquinoline-3-carboxylic acid monohydrate, a novel AMPA receptor antagonist, on glutamate-induced CA2+ responses and neurotoxicity in rat cortical and cerebellar granule neurons.
    Liljequist S; Cebers G; Kalda A
    Biochem Pharmacol; 1995 Nov; 50(11):1761-74. PubMed ID: 8615854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 6-substituted decahydroisoquinoline-3-carboxylic acids as potent and selective conformationally constrained NMDA receptor antagonists.
    Ornstein PL; Schoepp DD; Arnold MB; Augenstein NK; Lodge D; Millar JD; Chambers J; Campbell J; Paschal JW; Zimmerman DM
    J Med Chem; 1992 Sep; 35(19):3547-60. PubMed ID: 1404235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AMPA receptor antagonists and local cerebral glucose utilization in the rat.
    Browne SE; McCulloch J
    Brain Res; 1994 Mar; 641(1):10-20. PubMed ID: 8019834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a novel and highly potent noncompetitive AMPA receptor antagonist.
    Gitto R; Barreca ML; De Luca L; De Sarro G; Ferreri G; Quartarone S; Russo E; Constanti A; Chimirri A
    J Med Chem; 2003 Jan; 46(1):197-200. PubMed ID: 12502375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SPD 502: a water-soluble and in vivo long-lasting AMPA antagonist with neuroprotective activity.
    Nielsen EO; Varming T; Mathiesen C; Jensen LH; Moller A; Gouliaev AH; Wätjen F; Drejer J
    J Pharmacol Exp Ther; 1999 Jun; 289(3):1492-501. PubMed ID: 10336544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological characterization of the competitive GLUK5 receptor antagonist decahydroisoquinoline LY466195 in vitro and in vivo.
    Weiss B; Alt A; Ogden AM; Gates M; Dieckman DK; Clemens-Smith A; Ho KH; Jarvie K; Rizkalla G; Wright RA; Calligaro DO; Schoepp D; Mattiuz EL; Stratford RE; Johnson B; Salhoff C; Katofiasc M; Phebus LA; Schenck K; Cohen M; Filla SA; Ornstein PL; Johnson KW; Bleakman D
    J Pharmacol Exp Ther; 2006 Aug; 318(2):772-81. PubMed ID: 16690725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of LY293558, an AMPA receptor antagonist, on acute and chronic morphine dependence.
    McLemore GL; Kest B; Inturrisi CE
    Brain Res; 1997 Dec; 778(1):120-6. PubMed ID: 9462883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resolution, configurational assignment, and enantiopharmacology of 2-amino-3-[3-hydroxy-5-(2-methyl-2H- tetrazol-5-yl)isoxazol-4-yl]propionic acid, a potent GluR3- and GluR4-preferring AMPA receptor agonist.
    Vogensen SB; Jensen HS; Stensbøl TB; Frydenvang K; Bang-Andersen B; Johansen TN; Egebjerg J; Krogsgaard-Larsen P
    Chirality; 2000 Nov; 12(10):705-13. PubMed ID: 11054828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GluK1 antagonists from 6-(tetrazolyl)phenyl decahydroisoquinoline derivatives: in vitro profile and in vivo analgesic efficacy.
    Martinez-Perez JA; Iyengar S; Shannon HE; Bleakman D; Alt A; Clawson DK; Arnold BM; Bell MG; Bleisch TJ; Castaño AM; Del Prado M; Dominguez E; Escribano AM; Filla SA; Ho KH; Hudziak KJ; Jones CK; Mateo A; Mathes BM; Mattiuz EL; Ogden AM; Simmons RM; Stack DR; Stratford RE; Winter MA; Wu Z; Ornstein PL
    Bioorg Med Chem Lett; 2013 Dec; 23(23):6463-6. PubMed ID: 24140446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with in vivo activity.
    Stutzmann JM; Bohme GA; Boireau A; Damour D; Debono MW; Genevois-Borella A; Imperato A; Jimonet P; Pratt J; Randle JC; Ribeill Y; Vuilhorgne M; Mignani S
    Bioorg Med Chem Lett; 2000 May; 10(10):1133-7. PubMed ID: 10843235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.